Add Presentation to Slide Tray Presentation:
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Evaluating JIA Assessment Instruments (2 of 3)
Composite assessments combine results from multiple outcome measures to describe disease status. These assessments are used in both clinical research and in patient care settings. Examples are:
- ACR Pediatric response criteria (Peds 30, 50, 70, 90 etc.) — This assessment reports the degree of improvement from baseline status as a percentage.
- A consensus-based definition of remission
- Minimal disease activity
Keywords: ACR Pediatric | anti-rheumatic | antirheumatic | assessment | biologic DMARD | disease-modifying | DMARDs | flare | JCA | JIA | JRA | juvenile rheumatoid arthritis | non-biologic DMARD | nonbiologic DMARD | remission | rheumatic | TNF-alpha blockers | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.